BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 17499721)

  • 1. c-Myc is required for transformation of FDC-P1 cells by EGFRvIII.
    Rath O; Himmler A; Baum A; Sommergruber W; Beug H; Metz T
    FEBS Lett; 2007 May; 581(13):2549-56. PubMed ID: 17499721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
    Dolnikov A; Millington M; Sun LQ; Symonds G
    Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
    Moscatello DK; Montgomery RB; Sundareshan P; McDanel H; Wong MY; Wong AJ
    Oncogene; 1996 Jul; 13(1):85-96. PubMed ID: 8700557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
    Batra SK; Castelino-Prabhu S; Wikstrand CJ; Zhu X; Humphrey PA; Friedman HS; Bigner DD
    Cell Growth Differ; 1995 Oct; 6(10):1251-9. PubMed ID: 8845302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment.
    Theys J; Jutten B; Dubois L; Rouschop KM; Chiu RK; Li Y; Paesmans K; Lambin P; Lammering G; Wouters BG
    Radiother Oncol; 2009 Sep; 92(3):399-404. PubMed ID: 19616331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the epidermal growth factor receptor specific transcriptome: effect of receptor expression level and an activating mutation.
    Pedersen MW; Pedersen N; Damstrup L; Villingshøj M; Sønder SU; Rieneck K; Bovin LF; Spang-Thomsen M; Poulsen HS
    J Cell Biochem; 2005 Oct; 96(2):412-27. PubMed ID: 16075456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII.
    Mukherjee J; DeSouza LV; Micallef J; Karim Z; Croul S; Siu KW; Guha A
    Cancer Res; 2009 Nov; 69(22):8545-54. PubMed ID: 19903856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras.
    Kim SH; Nakagawa H; Navaraj A; Naomoto Y; Klein-Szanto AJ; Rustgi AK; El-Deiry WS
    Cancer Res; 2006 Nov; 66(21):10415-24. PubMed ID: 17079462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B; Chen J; Zhang X; Cao J
    Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation.
    Ning Y; Zeineldin R; Liu Y; Rosenberg M; Stack MS; Hudson LG
    Cancer Res; 2005 Oct; 65(20):9280-6. PubMed ID: 16230389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between MYC and transforming growth factor alpha alter the growth and tumorigenicity of liver progenitor cells.
    Cheung RS; Brooling JT; Johnson MM; Riehle KJ; Campbell JS; Fausto N
    Carcinogenesis; 2007 Dec; 28(12):2624-31. PubMed ID: 17698969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor.
    Bermudez Y; Yang H; Cheng JQ; Kruk PA
    Growth Factors; 2008 Feb; 26(1):1-11. PubMed ID: 18365874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha-stimulated membrane type 1-matrix metalloproteinase production is modulated by epidermal growth factor receptor signaling in human gingival fibroblasts.
    Smith PC; Guerrero J; Tobar N; Cáceres M; González MJ; Martínez J
    J Periodontal Res; 2009 Feb; 44(1):73-80. PubMed ID: 19515020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
    Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
    Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells.
    Uttamsingh S; Bao X; Nguyen KT; Bhanot M; Gong J; Chan JL; Liu F; Chu TT; Wang LH
    Oncogene; 2008 Apr; 27(18):2626-34. PubMed ID: 17982486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intermediary role of proHB-EGF shedding in growth factor-induced c-Myc gene expression.
    Nanba D; Inoue H; Shigemi Y; Shirakata Y; Hashimoto K; Higashiyama S
    J Cell Physiol; 2008 Feb; 214(2):465-73. PubMed ID: 17674363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infection with a Kirsten-retrovirus can induce a multiplicity of tumorigenic phenotypes in the interleukin-3-dependent FDC-P1 cells.
    Duménil D; Neel H; Lacout C; Dautry F
    Exp Hematol; 1994 Feb; 22(2):178-85. PubMed ID: 8299738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.